← ANALYST RATINGS · TIPRANKS
Castle Biosciences (CSTL): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $45.40, the highest $57.00, the lowest $36.00. The average is +42.1% from the last price of $31.96.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $37.00 → $38.00+2.7% | Buy | +18.9% | Reiterated | 11.10.26on TipRanks 01:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 → $38.00+2.7% | Buy | +18.9% | Upgrade | 11.10.26on TipRanks 01:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $37.00 → $38.00+2.7% | Buy | +18.9% | Upgrade | 11.10.26on TipRanks 01:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $35.00 → $36.00+2.9% | Hold | +12.6% | Reiterated | 11.10.26on TipRanks 01:06 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $37.00 → $38.00+2.7% | Buy | +18.9% | Reiterated | 11.10.26on TipRanks 01:06 | — | |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $57.00 | Buy | +78.3% | Reiterated | 01.10.26on TipRanks 09:10 | −1.0%next day +0.1% · 5 days −5.7% | ↗ |
| Max Masucci★★★★★★★★★★#2606 · hits 42% · avg +8.5% | Roth MKM | $40.00 → $50.00+25.0% | Buy | +56.4% | Reiterated | 22.09.26on TipRanks 09:10 | −0.4%next day +0.8% · 5 days +1.3% | ↗ |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $34.00 → $36.00+5.9% | Buy | +12.6% | Upgrade | 20.08.26on TipRanks 02:05 | — | |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $40.00 → $44.00+10.0% | Buy | +37.7% | Reiterated | 03.08.26on TipRanks 07:15 | +7.1%next day +0.8% · 5 days +4.4% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $40.00 | Buy | +25.2% | Reiterated | 02.08.26on TipRanks Aug 3 07:45 | +7.1%next day +0.8% · 5 days +4.4% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $43.00 → $36.00−16.3% | Buy | +12.6% | Reiterated | 31.07.26on TipRanks 07:36 | +3.8%next day +7.1% · 5 days +10.9% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $50.00 → $35.00−30.0% | Buy | +9.5% | Reiterated | 29.05.26on TipRanks 10:40 | −4.9%next day −0.8% · 5 days +2.2% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $47.00 | Buy | +47.1% | Reiterated | 07.05.26on TipRanks 07:00 | −22.0%next day +2.2% · 5 days −4.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Castle Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.40 at a price of $35.53 (+27.8%); now: $45.40 at $31.96 (+42.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 2 | 1 | 1 |
| Buy | 0 | 0 | 2 | 4 | 5 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.35 (from $-0.42 to $-0.25). Last quarter: $-0.07.
Sales
Next quarter’s sales estimate — $92M (from $91M to $93M). Last quarter: $104M.
Best top-analyst consensus in the sector · Healthcare
About Castle Biosciences
- CEO: Derek J. Maetzold
- Employees: 1,002
- 1500 W. Parkwood Ave, Friendswood, TX, 77546, US
- castlebiosciences.com
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Data from the stock’s TipRanks forecast page, read 76 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗